Zacks Investment Research cut shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.

According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

Several other research analysts also recently commented on ACRS. BidaskClub upgraded shares of Aclaris Therapeutics from a strong sell rating to a sell rating in a report on Saturday, December 1st. Cantor Fitzgerald set a $50.00 target price on shares of Aclaris Therapeutics and gave the stock a buy rating in a report on Friday, December 21st. Finally, ValuEngine downgraded shares of Aclaris Therapeutics from a hold rating to a sell rating in a report on Wednesday, January 2nd. Three equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. Aclaris Therapeutics has a consensus rating of Hold and an average price target of $35.94.

Shares of ACRS opened at $5.63 on Wednesday. The firm has a market capitalization of $242.75 million, a P/E ratio of -2.25 and a beta of 1.24. Aclaris Therapeutics has a one year low of $5.49 and a one year high of $21.97.

Several large investors have recently bought and sold shares of ACRS. Bank of New York Mellon Corp increased its holdings in shares of Aclaris Therapeutics by 8.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 423,001 shares of the biotechnology company’s stock worth $8,447,000 after purchasing an additional 31,339 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of Aclaris Therapeutics by 40.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 103,185 shares of the biotechnology company’s stock worth $1,500,000 after purchasing an additional 29,645 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Aclaris Therapeutics by 2.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 188,380 shares of the biotechnology company’s stock worth $2,735,000 after purchasing an additional 4,351 shares during the period. BlackRock Inc. increased its holdings in shares of Aclaris Therapeutics by 8.9% during the 3rd quarter. BlackRock Inc. now owns 2,517,412 shares of the biotechnology company’s stock worth $36,551,000 after purchasing an additional 205,771 shares during the period. Finally, Rosenblum Silverman Sutton S F Inc. CA increased its holdings in shares of Aclaris Therapeutics by 21.0% during the 3rd quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 89,500 shares of the biotechnology company’s stock worth $1,300,000 after purchasing an additional 15,515 shares during the period. Institutional investors own 95.20% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Further Reading: Treasury Bonds

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.